首页|卡培他滨单药或联合方案治疗晚期乳腺癌的临床疗效观察

卡培他滨单药或联合方案治疗晚期乳腺癌的临床疗效观察

扫码查看
目的 探究晚期乳腺癌患者应用卡培他滨和卡培他滨联合方案治疗的临床效果与安全性.方法 随机抽取浙江大学明州医院2014年2月~2016年3月收治的晚期乳腺癌患者82例,随机分为对照组和研究组,每组41例.对照组采用卡培他滨单药治疗;研究组应用卡培他滨联合多西紫杉醇治疗.对比2组患者的治疗效果、安全性、不良反应等情况.结果 研究组治疗有效率为56.48%明显优于对照组的34.28%,差异有统计学意义(P<0.05).对照组治疗后并发症的发生率为40.22%明显高于研究组的18.04%,差异有统计学意义(P<0.05).结论 卡培他滨联合多西紫杉醇治疗晚期乳腺癌,效果良好,不良反应发生率低.
Clinical observation of capecitabine monotherapy or combination regimen in the treatment of advanced breast cancer
Objective To explore the clinical effect and safety of patients with advanced breast cancer with capecitabine and gemcitabine combined with capecitabine treatment scheme. Methods 82 cases of patients with advanced breast cancer received treatment in our hospital from February 2014 to March 2016 were randomly selected and were randomly divided into control group and study group, 41 cases in each group.The control group using capecitabine monotherapy, the study group used capecitabine combined with docetaxel treatment. The therapeutic effects, safety and adverse reactions of the two groups were compared. Results The effective rate of treatment in the study group was 56.48 %, significantly better than that in the control group(34.28 %), the difference was statistically significant, The incidence of complications after treatment in the control group was 40.22 %, significantly higher than that in the study group (18.04 %), and the difference was statistically significant (P<0.05). Conclusion Capecitabine combined with docetaxel in the treatment of advanced breast cancer has good effect and low incidence of adverse reactions. It is worthy of recommendation and Application.

capecitabinecombination therapydocetaxeladvanced breast cancer

朱柯斌

展开 >

浙江大学明州医院 普外科,浙江 宁波 315101

卡培他滨 联合治疗 多西紫杉醇 晚期乳腺癌

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(10)
  • 1
  • 8